US Pharma MarketingPatrick Velliky is confident the No Surprises Act is lowering out-of-network spending, despite research to the contrary. HaloMD’s chief external affairs officer responds to criticisms of his analysis, and of his company.
Why HaloMD became a target — and what its top lobbyist says critics get wrong
Patrick Velliky is confident the No Surprises Act is lowering out-of-network spending, despite research to the contrary. HaloMD’s chief external affairs officer responds to criticisms of his analysis, and of his company.
Source: Healthcare Dive